Abstract LBA5
Background
Although current guidelines recommend deciding on postmastectomy radiation therapy (PMRT) or regional nodal irradiation (RNI) after breast conserving surgery (BCS) depending on initial clinical stages before neoadjuvant chemotherapy (NAC), it is controversial whether adjuvant radiation therapy (RT) can be omitted for patients with excellent response. This retrospective study evaluates if PMRT or RNI after BCS significantly reduces locoregional recurrence rate in patients with clinically positive, pathologic negative lymph nodes (LNs) after NAC.
Methods
From 1999 to 2016, 1831 women with breast cancer underwent NAC and surgery. Of them, 427 patients with clinically node-positive and pN0 disease were analyzed.
Results
Median follow-up was 65.4 months. The 5-year locoregional relapse (LRRFS) and disease-free survival (DFS) rates were 96.9% and 88.3%, respectively. In patients with an initial nodal stage of cN2-3, RT significantly reduced LRR, with a hazard ratio (HR) of 0.132 (p = 0.009). However, RT was not shown to be effective in the cN1 group (HR = 0.893, p = 0.9). RT did not improve DFS, regardless of cN stage. PMRT/RNI was defined as the combined set of patients who received PMRT or received RT, including regional nodal irradiation (RNI) after BCS; the effects of PMRT/RNI were analyzed. PMRT/RNI significantly reduced LRR in the cN2-3 patient group (HR = 0.175, p = 0.03), but there was no significant effect for cN1 disease. Among 173 patients who underwent mastectomy, there were 108 and 65 patients, respectively, who received RT or no RT. Among all patients, PMRT had no effect on LRR (p = 0.7). However, among cN2-3 patients, PMRT significantly lowered LRR (HR = 0.10, p = 0.02), while there was no significant effect in cN1 patients.
Conclusions
In analysis of all patients and of mastectomy patients, RT consistently improved local control rate in the cN2 and higher patient group. Similar results were obtained in the combined analysis of PMRT and RNI after BCS. Therefore, in ypN0 patients graded cN2 or higher, RT including RNI is predicted to be absolutely necessary. No conclusion could be reached for cN1 disease.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
De-escalating axillary surgery according to neoadjuvant single or dual HER2 blockade in clinically node-positive, HER2-positive breast cancer
Presenter: Chihwan Cha
Session: Mini Oral session - Breast cancer
Resources:
Slides
Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)
Presenter: Yen-Shen Lu
Session: Mini Oral session - Breast cancer
Resources:
Slides
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with advanced breast cancer (ABC): Final results from EVEREXES
Presenter: Young-Hyuck Im
Session: Mini Oral session - Breast cancer
Resources:
Slides
Protective effects of bisoprolol against acute anthracycline-induced cardiotoxicity: A randomized control study
Presenter: Saleh Sandoughdaran
Session: Mini Oral session - Breast cancer
Resources:
Slides
Integrative analysis of metabolic subtypes in triple-negative breast cancer reveals new therapeutic strategies
Presenter: Yue Gong
Session: Mini Oral session - Breast cancer
Resources:
Slides